Spine BioPharma
Marc Viscogliosi, Chairman & CEO

Spine BioPharma is committed to developing non-surgical/non-opioid treatments that will reduce pain, restore function, and slow or stop pathological spinal disease progression. Spine BioPharma’s lead candidate, SB-01 For Injection, is a first-in-class treatment of degenerative disc disease, offering potential clinical benefits of pain relief, restoration of function and potential prevention of disease progression.

spinebiopharma.com